These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 28505045)

  • 21. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.
    Esler M
    J Am Soc Hypertens; 2014 Aug; 8(8):593-8. PubMed ID: 25151320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future of interventional management of hypertension: threats and opportunities.
    Briasoulis A; Bakris G
    Curr Vasc Pharmacol; 2014 Jan; 12(1):69-76. PubMed ID: 23905592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistant Hypertension and Renal Nerve Denervation.
    Denker MG; Cohen DL
    Methodist Debakey Cardiovasc J; 2015; 11(4):240-4. PubMed ID: 27057294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and performance of the second generation EnligHTN™ Renal Denervation System in patients with drug-resistant, uncontrolled hypertension.
    Worthley SG; Wilkins GT; Webster MW; Montarello JK; Delacroix S; Whitbourn RJ; Warren RJ
    Atherosclerosis; 2017 Jul; 262():94-100. PubMed ID: 28531827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.
    Kandzari DE; Bhatt DL; Sobotka PA; O'Neill WW; Esler M; Flack JM; Katzen BT; Leon MB; Massaro JM; Negoita M; Oparil S; Rocha-Singh K; Straley C; Townsend RR; Bakris G
    Clin Cardiol; 2012 Sep; 35(9):528-35. PubMed ID: 22573363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Renal artery denervation for treating refractory hypertension].
    Benamer H; Louvard Y; Garot P; Unterseeh T; Hovasse T; Lefèvre T; Chevalier B; Morice MC
    Ann Cardiol Angeiol (Paris); 2011 Dec; 60(6):354-60. PubMed ID: 22040858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal denervation.
    Olsen LK; Kamper AL; Svendsen JH; Feldt-Rasmussen B
    Eur J Intern Med; 2015 Mar; 26(2):95-105. PubMed ID: 25676808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal Denervation.
    Hameed MA; Dasgupta I
    Adv Exp Med Biol; 2017; 956():261-277. PubMed ID: 27815927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiology of renal denervation procedures: from renal nerve anatomy to procedural parameters.
    Ammar S; Ladich E; Steigerwald K; Deisenhofer I; Joner M
    EuroIntervention; 2013 May; 9 Suppl R():R89-95. PubMed ID: 23732162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of renal denervation for the treatment of resistant hypertension.
    McLellan AJ; Kistler PM; Walton AS; Schlaich MP
    J Hum Hypertens; 2014 Apr; 28(4):218-23. PubMed ID: 24088716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon.
    Bunte MC; Infante de Oliveira E; Shishehbor MH
    JACC Cardiovasc Interv; 2013 Jan; 6(1):1-9. PubMed ID: 23266234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing and efficacy of alternative methods of sympathetic blockade.
    Briasoulis A; Bakris GL
    Curr Hypertens Rep; 2012 Oct; 14(5):455-61. PubMed ID: 22833367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The "resistant hypertension team": focus on a multidisciplinary approach to hypertension.
    Potthoff SA; Rump LC; Vonend O
    EuroIntervention; 2013 May; 9 Suppl R():R48-53. PubMed ID: 23732155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of renal denervation in cardiology and beyond: An updated comprehensive review and future directives.
    Goyal A; Jain H; Verma A; Jain J; Shamim U; Kanagala SG; Motwani J; Dey RC; Chunawala Z; Sohail AH; Belur AD
    Curr Probl Cardiol; 2024 Feb; 49(2):102196. PubMed ID: 37952794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension.
    Lobo MD; de Belder MA; Cleveland T; Collier D; Dasgupta I; Deanfield J; Kapil V; Knight C; Matson M; Moss J; Paton JF; Poulter N; Simpson I; Williams B; Caulfield MJ; ; ; ;
    Heart; 2015 Jan; 101(1):10-6. PubMed ID: 25431461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
    ; Esler MD; Krum H; Sobotka PA; Schlaich MP; Schmieder RE; Böhm M
    Lancet; 2010 Dec; 376(9756):1903-9. PubMed ID: 21093036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal denervation for human hypertension: is there a future?
    Izzo JL; Tobe SW
    J Am Soc Hypertens; 2016 May; 10(5):390-2. PubMed ID: 27049792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial.
    Yerasi C; Baker NC; Jonnalagadda AK; Torguson R; Singh S; Vies J; Waksman R
    J Am Soc Hypertens; 2015 Dec; 9(12):959-65. PubMed ID: 26687550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications.
    Kandzari DE; Kario K; Mahfoud F; Cohen SA; Pilcher G; Pocock S; Townsend R; Weber MA; Böhm M
    Am Heart J; 2016 Jan; 171(1):82-91. PubMed ID: 26699604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients' adherence.
    Kjeldsen SE; Fadl Elmula FE; Os I; Persu A; Jin Y; Staessen JA
    Eur Heart J Cardiovasc Pharmacother; 2015 Jan; 1(1):48-56. PubMed ID: 27533966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.